These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 23523344)
61. Perspectives on Challenges to Cell Therapy Development in Taiwan: Strengthening Evidential Standards and Ways Forward. Abolarinwa BA; Shaw MK; Lee CH Front Bioeng Biotechnol; 2021; 9():789043. PubMed ID: 34976978 [TBL] [Abstract][Full Text] [Related]
62. Implementing Horizon Scanning as a tool for the strategic development of regulatory guidelines for nanotechnology-enabled health products. Rodríguez-Gómez FD; Monferrer D; Penon O; Rivera-Gil P Front Med (Lausanne); 2023; 10():1308047. PubMed ID: 38298514 [TBL] [Abstract][Full Text] [Related]
63. Quality considerations for recombinant DNA-derived biological therapeutic products: a control perspective on cytokines. Mire-Sluis A; Thorpe R BioDrugs; 1999 Jun; 11(6):367-76. PubMed ID: 18031148 [TBL] [Abstract][Full Text] [Related]
64. Regulation of allergen products in Canada: an overview of the current and the proposed regulatory frameworks (draft guidance). Green N Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess; 2013; 97():27-30. PubMed ID: 24912309 [No Abstract] [Full Text] [Related]
65. Natural health products are subjected to rigorous process prior to market. Laidlaw M CMAJ; 2017 Oct; 189(40):E1267. PubMed ID: 29018087 [No Abstract] [Full Text] [Related]
66. [THE BIOLOGICAL PRODUCTS AND PUBLIC HEALTH]. DE OLIVEIRA JC J Soc Cienc Med Lisb; 1963 Dec; 127():751-62. PubMed ID: 14115002 [No Abstract] [Full Text] [Related]
67. Ten years on from the 1992 'Manual handling operations regulations': a perspective from higher education in the UK. Kneafsey R; Baker C; Robinson J Nurse Educ Pract; 2003 Sep; 3(3):121-2. PubMed ID: 19038111 [No Abstract] [Full Text] [Related]
69. Exploration of facilitators and barriers to the regulatory frameworks of dietary and herbal supplements: a scoping review. Ng JY; Kim M; Suri A J Pharm Policy Pract; 2022 Sep; 15(1):55. PubMed ID: 36064655 [TBL] [Abstract][Full Text] [Related]
70. Postmarket surveillance of natural health products in Canada: clinical and federal regulatory perspectives. Murty M Can J Physiol Pharmacol; 2007 Sep; 85(9):952-5. PubMed ID: 18066142 [TBL] [Abstract][Full Text] [Related]
71. The Canadian Natural Health Products (NHP) regulations: industry perceptions and compliance factors. Laeeque H; Boon H; Kachan N; Cohen JC; D'Cruz J BMC Health Serv Res; 2006 May; 6():63. PubMed ID: 16734916 [TBL] [Abstract][Full Text] [Related]
72. Regulation of natural health products in Canada. Smith A; Jogalekar S; Gibson A J Ethnopharmacol; 2014 Dec; 158 Pt B():507-10. PubMed ID: 24969823 [TBL] [Abstract][Full Text] [Related]
73. Risk management frameworks for human health and environmental risks. Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953 [TBL] [Abstract][Full Text] [Related]
74. Governance of natural health products regulation: an iterative process. Walji R; Wiktorowicz M Health Policy; 2013 Jun; 111(1):86-94. PubMed ID: 23523344 [TBL] [Abstract][Full Text] [Related]